Targeting the hallmarks of ovarian cancer: The big picture

Gynecologic Oncology

Volumn 142, Issue 1, 2016, Pages 176-183

  Petrillo, M ^a   Nero, C ^a   Amadio, G ^a   Gallo, D ^a   Fagotti, A ^a,b   Scambia, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Cancer hallmarks; Epithelial ovarian cancer; Molecular pathways

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE INHIBITOR; FOLATE RECEPTOR; GLYCOPROTEIN P INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NERVE CELL ADHESION MOLECULE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN SYNTHASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; CELL DEATH; CINAHL; COCHRANE LIBRARY; EMBASE; ENERGY METABOLISM; GENOMIC INSTABILITY; HUMAN; MEDLINE; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TUMOR ESCAPE; TUMOR INVASION; FEMALE; GENETICS; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); OVARIAN NEOPLASMS; VASCULARIZATION;

FEMALE; GENOMIC INSTABILITY; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS;

EID: 84962678736     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.03.037     Document Type: Review

References (50)

1. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
2. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
3. P.C. Fong, and et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N. Engl. J. Med. 361 2009 123 134
4. S.B. Kaye, J. Lubinski, U. Matulonis, and et al. Phase II, open-label, randomized, multicenter study comparing the effi cacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer J. Clin. Oncol. 30 2012 372 379
5. J. Ledermann, P. Harter, and C. Gourley Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N. Engl. J. Med. 366 2012 1382 1392
6. J. Ledermann, P. Harter, C. Gourley, and et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol. 15 2014 852 861
7. K.A. Gelmon, M. Tischkowitz, H. Mackay, and et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, nonrandomised study Lancet Oncol. 12 2011 852 861
8. I.A. McNeish, A.M. Oza, R.L. Coleman, and et al. Results of ARIEL2: a phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis J. Clin. Oncol. 33 2015 (suppl; abstr 5508)
9. K.M. Bell-McGuinn, W.E. Brady, R.J. Schilder, and et al. A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube or primary peritoneal cancer: an NGR oncology/gynecology oncology group study J. Clin. Oncol. 33 2015 (suppl; abstr 5507)
10. S.K. Sandhu, W.R. Schelman, L.R. Molife, and et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial Lancet Oncol. 14 2013 882 892
11. F. Legge, A. Paglia, M. D'Asta, G. Fuoco, G. Scambia, and G. Ferrandina Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients BMC Cancer 11 2011 214
12. O. Alper, E.S. Bergmann-Leitner, T.A. Bennett, and et al. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells J. Natl. Cancer Inst. 93 2001 1375 1384
13. S.D. Pack, O.M. Alper, K. Stromberg, and et al. Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line Cancer Res. 64 2004 789 794
14. P. Pautier, F. Joly, P. Kerbrat, and et al. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074) Gynecol. Oncol. 116 2010 157 162
15. I.B. Vergote, A. Jimeno, F. Joly, and et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European organisation for research and treatment of cancer - gynaecological cancer group, and gynecologic cancer intergroup study J. Clin. Oncol. 32 2014 320 326
16. H. Hirte, A. Oza, K. Swenerton, and et al. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149) Gynecol. Oncol. 118 2010 308 312
17. E. Warner, L. Liebes, B. Levinson, A. Downey, A. Tiersten, and F. Muggia Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness Oncologist 19 2014 250
18. M.A. Bookman, K.M. Darcy, D. Clarke-Pearson, R.A. Boothby, and I.R. Horowitz Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group J. Clin. Oncol. 21 2003 283 290
19. S. Makhija, L.C. Amler, D. Glenn, and et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer J. Clin. Oncol. 28 2010 1215 1223
20. A.A. Garcia, M.W. Sill, H.A. Lankes, and et al. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study Gynecol. Oncol. 124 2012 569 574
21. S.J. Weroha, A.L. Oberg, K.L. Ziegler, and et al. Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma Gynecol. Oncol. 122 2011 116 120
22. S.B. Kaye, C.J. Poole, A. Dańska-Bidzińska, and et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer Ann. Oncol. 24 2013 145 152
23. D.K. Armstrong, A.J. White, S.C. Weil, M. Phillips, and R.L. Coleman Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer Gynecol. Oncol. 129 2013 452 458
24. M. Sun, G. Wang, J.E. Paciga, and et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells Am. J. Pathol. 159 2001 431 437
25. D.A. Altomare, S. Tanno, A. De Rienzo, and et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas J. Cell. Biochem. 87 2002 470 476
26. D.A. Altomare, H.Q. Wang, K.L. Skele, and et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth Oncogene 23 2004 5853 5857
27. Masashi Takano, Hiroko Kouta, Yuji Ikeda, and et al. Combination chemotherapy with temsirolimus and trabectedin for recurrenmt clear cell carcinoma of the ovary: a phase II single arm clinical trial J. Clin. Oncol. 32 5s 2014 (suppl; abs 5517)
28. J. Farley, W.E. Brady, V. Vathipadiekal, and et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study Lancet Oncol. 14 2013 134 140
29. Integrated genomic analyses of ovarian carcinoma. Cancer Genome Atlas Research Network Nature 474 2011 609 615
30. K.C. Bible, P.P. Peethambaram, A.L. Oberg, and et al. A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261 Gynecol. Oncol. 127 2012 55 62
31. T.S. Latha, K. Panati, D.S. Gowd, M.C. Reddy, and D. Lomada Ovarian cancer biology and immunotherapy Int. Rev. Immunol. 33 2014 428 440
32. A. Varga, S.A. Piha-paul, P.A. Ott, and et al. Antitumor activity and safety of pembrolizumab in patients with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study J. Clin. Oncol. 33 2015 (suppl; abstr 5510)
33. M.L. Disis, M.R. Patel, S. Pant, and et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial J. Clin. Oncol. 33 2015 (supp; abstr 5509)
34. H. Nishio, T. Yaguchi, J. Sugiyama, and et al. Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor Br. J. Cancer 110 2014 2965 2974
35. D.S. Dizon, L. Damstrup, N.J. Finkler, and et al. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer Int. J. Gynecol. Cancer 22 2012 979 986
36. D.S. Dizon, J.A. Blessing, R.T. Penson, and et al. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a gynecologic oncology group study Gynecol. Oncol. 125 2012 367 371
37. C. Falandry, M. Bonnefoy, G. Freyer, and E. Gilson Biology of cancer and aging: a complex association with cellular senescence J. Clin. Oncol. 32 2014 2604 2610
38. M.J. Mulvihill, A. Cooke, M. Rosenfeld-Franklin, and et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor Future Med. Chem. 1 2009 1153 1171
39. E. Pujade-Lauraine, F. Hilpert, B. Weber, and et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial J. Clin. Oncol. 32 2014 1302 1308
40. R.A. Burger, M.F. Brady, M.A. Bookman, and et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N. Engl. J. Med. 365 2011 2473 2483
41. D. Stark, M. Nankivell, E. Pujade-Lauraine, and et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on ovarian Neoplasms (ICON7) phase 3 randomised trial Lancet Oncol. 14 2013 236 243
42. C. Aghajanian, S.V. Blank, B.A. Goff, and et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J. Clin. Oncol. 30 2012 2039 2045
43. M.J. Birrer, Y.J. Choi, M.F. Brady, and et al. Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin-paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC) J. Clin. Oncol. 33 2015 (suppl; abstr 5505)
44. B.J. Monk, A. Poveda, I. Vergote, and et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial Lancet Oncol. 15 2014 799 808
45. J.F. Liu, W.T. Barry, M. Birrer, and et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomized phase 2 study Lancet Oncol. 15 2014 1207 1214
46. S. Pignata, D. Lorusso, G. Scambia, and et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. MITO 11 investigators Lancet Oncol. 16 2015 561 568
47. A. Du Bois, A. Floquet, J.W. Kim, and et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer J. Clin. Oncol. 32 2014 3374 3382
48. M.J. De Herdt, and R.J. de Jong Baatenburg HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma Front. Biosci. 13 2008 2516 2526
49. X. Chen, Y. Qian, and S. Wu The Warburg effect: evolving interpretations of an established concept Free Radic. Biol. Med. 79 2015 253 263
50. J.A. Menendez, and T. Alarcón Metabostemness: a new cancer hallmark Front. Oncol. 4 2014 262